Antiandrogen therapy in metastatic male breast cancer: results from an updated analysis in an expanded case series

Luigi Di Lauro, Patrizia Vici, Maddalena Barba, Laura Pizzuti, Domenico Sergi, Massimo Rinaldi, Anna Di Benedetto, Isabella Sperduti, Abeer M. Shaaban, Valerie Speirs, Marcella Mottolese, Ruggero De Maria, Marcello Maugeri-Saccà

Research output: Contribution to journalArticle

Abstract

Male breast cancer is a rare disease treated as hormone receptor-positive female breast cancer. The characterization of breast cancer at the molecular level has lately revealed gender-related differences. As the androgen receptor is emerging as a potential oncogenic driver in male breast cancer, we analyzed efficacy data from metastatic patients treated with antiandrogens. We evaluated the activity of cyproterone acetate, either as a monotherapy or combined with a GnRH analog, in 36 metastatic male breast cancer patients. Fourteen patients were treated with cyproterone acetate as monotherapy and 22 patients with complete androgen blockade. We recorded 4 complete responses and 15 partial responses, for an overall response rate of 52.8 % (95 % CI, 36.5–69.4). Stable disease was reported in 11 patients. Median PFS was 8.9 months (95 % CI, 6.1–11.7), and median OS was 24.3 months (95 % CI, 22.5–26.1). Data on androgen receptor expression were available for 7 patients. All the 4 patients with androgen receptor-expressing tumors had a clinical benefit, including a patient with an estrogen receptor-negative disease. Conversely, none of the 3 patients with androgen receptor-negative tumors had a tumor response. Antiandrogen-based therapy showed efficacy in metastatic male breast cancer patients. Our results encourage considering antiandrogens in the therapeutic continuum, especially if supported by androgen receptor expression.

Original languageEnglish
Pages (from-to)73-80
Number of pages8
JournalBreast Cancer Research and Treatment
Volume148
Issue number1
DOIs
Publication statusPublished - Oct 14 2014

Fingerprint

Male Breast Neoplasms
Androgen Antagonists
Androgen Receptors
Cyproterone Acetate
Therapeutics
Breast Neoplasms
Neoplasms
Rare Diseases
Gonadotropin-Releasing Hormone
Estrogen Receptors
Androgens
Hormones

Keywords

  • Androgen receptor
  • Antiandrogens
  • Cyproterone acetate
  • GnRH analogs
  • Metastatic male breast cancer

ASJC Scopus subject areas

  • Oncology
  • Cancer Research
  • Medicine(all)

Cite this

Antiandrogen therapy in metastatic male breast cancer : results from an updated analysis in an expanded case series. / Di Lauro, Luigi; Vici, Patrizia; Barba, Maddalena; Pizzuti, Laura; Sergi, Domenico; Rinaldi, Massimo; Di Benedetto, Anna; Sperduti, Isabella; Shaaban, Abeer M.; Speirs, Valerie; Mottolese, Marcella; De Maria, Ruggero; Maugeri-Saccà, Marcello.

In: Breast Cancer Research and Treatment, Vol. 148, No. 1, 14.10.2014, p. 73-80.

Research output: Contribution to journalArticle

Di Lauro, Luigi ; Vici, Patrizia ; Barba, Maddalena ; Pizzuti, Laura ; Sergi, Domenico ; Rinaldi, Massimo ; Di Benedetto, Anna ; Sperduti, Isabella ; Shaaban, Abeer M. ; Speirs, Valerie ; Mottolese, Marcella ; De Maria, Ruggero ; Maugeri-Saccà, Marcello. / Antiandrogen therapy in metastatic male breast cancer : results from an updated analysis in an expanded case series. In: Breast Cancer Research and Treatment. 2014 ; Vol. 148, No. 1. pp. 73-80.
@article{5ffe44ef70e549589216fff97cf426c6,
title = "Antiandrogen therapy in metastatic male breast cancer: results from an updated analysis in an expanded case series",
abstract = "Male breast cancer is a rare disease treated as hormone receptor-positive female breast cancer. The characterization of breast cancer at the molecular level has lately revealed gender-related differences. As the androgen receptor is emerging as a potential oncogenic driver in male breast cancer, we analyzed efficacy data from metastatic patients treated with antiandrogens. We evaluated the activity of cyproterone acetate, either as a monotherapy or combined with a GnRH analog, in 36 metastatic male breast cancer patients. Fourteen patients were treated with cyproterone acetate as monotherapy and 22 patients with complete androgen blockade. We recorded 4 complete responses and 15 partial responses, for an overall response rate of 52.8 {\%} (95 {\%} CI, 36.5–69.4). Stable disease was reported in 11 patients. Median PFS was 8.9 months (95 {\%} CI, 6.1–11.7), and median OS was 24.3 months (95 {\%} CI, 22.5–26.1). Data on androgen receptor expression were available for 7 patients. All the 4 patients with androgen receptor-expressing tumors had a clinical benefit, including a patient with an estrogen receptor-negative disease. Conversely, none of the 3 patients with androgen receptor-negative tumors had a tumor response. Antiandrogen-based therapy showed efficacy in metastatic male breast cancer patients. Our results encourage considering antiandrogens in the therapeutic continuum, especially if supported by androgen receptor expression.",
keywords = "Androgen receptor, Antiandrogens, Cyproterone acetate, GnRH analogs, Metastatic male breast cancer",
author = "{Di Lauro}, Luigi and Patrizia Vici and Maddalena Barba and Laura Pizzuti and Domenico Sergi and Massimo Rinaldi and {Di Benedetto}, Anna and Isabella Sperduti and Shaaban, {Abeer M.} and Valerie Speirs and Marcella Mottolese and {De Maria}, Ruggero and Marcello Maugeri-Sacc{\`a}",
year = "2014",
month = "10",
day = "14",
doi = "10.1007/s10549-014-3138-9",
language = "English",
volume = "148",
pages = "73--80",
journal = "Breast Cancer Research and Treatment",
issn = "0167-6806",
publisher = "Springer New York LLC",
number = "1",

}

TY - JOUR

T1 - Antiandrogen therapy in metastatic male breast cancer

T2 - results from an updated analysis in an expanded case series

AU - Di Lauro, Luigi

AU - Vici, Patrizia

AU - Barba, Maddalena

AU - Pizzuti, Laura

AU - Sergi, Domenico

AU - Rinaldi, Massimo

AU - Di Benedetto, Anna

AU - Sperduti, Isabella

AU - Shaaban, Abeer M.

AU - Speirs, Valerie

AU - Mottolese, Marcella

AU - De Maria, Ruggero

AU - Maugeri-Saccà, Marcello

PY - 2014/10/14

Y1 - 2014/10/14

N2 - Male breast cancer is a rare disease treated as hormone receptor-positive female breast cancer. The characterization of breast cancer at the molecular level has lately revealed gender-related differences. As the androgen receptor is emerging as a potential oncogenic driver in male breast cancer, we analyzed efficacy data from metastatic patients treated with antiandrogens. We evaluated the activity of cyproterone acetate, either as a monotherapy or combined with a GnRH analog, in 36 metastatic male breast cancer patients. Fourteen patients were treated with cyproterone acetate as monotherapy and 22 patients with complete androgen blockade. We recorded 4 complete responses and 15 partial responses, for an overall response rate of 52.8 % (95 % CI, 36.5–69.4). Stable disease was reported in 11 patients. Median PFS was 8.9 months (95 % CI, 6.1–11.7), and median OS was 24.3 months (95 % CI, 22.5–26.1). Data on androgen receptor expression were available for 7 patients. All the 4 patients with androgen receptor-expressing tumors had a clinical benefit, including a patient with an estrogen receptor-negative disease. Conversely, none of the 3 patients with androgen receptor-negative tumors had a tumor response. Antiandrogen-based therapy showed efficacy in metastatic male breast cancer patients. Our results encourage considering antiandrogens in the therapeutic continuum, especially if supported by androgen receptor expression.

AB - Male breast cancer is a rare disease treated as hormone receptor-positive female breast cancer. The characterization of breast cancer at the molecular level has lately revealed gender-related differences. As the androgen receptor is emerging as a potential oncogenic driver in male breast cancer, we analyzed efficacy data from metastatic patients treated with antiandrogens. We evaluated the activity of cyproterone acetate, either as a monotherapy or combined with a GnRH analog, in 36 metastatic male breast cancer patients. Fourteen patients were treated with cyproterone acetate as monotherapy and 22 patients with complete androgen blockade. We recorded 4 complete responses and 15 partial responses, for an overall response rate of 52.8 % (95 % CI, 36.5–69.4). Stable disease was reported in 11 patients. Median PFS was 8.9 months (95 % CI, 6.1–11.7), and median OS was 24.3 months (95 % CI, 22.5–26.1). Data on androgen receptor expression were available for 7 patients. All the 4 patients with androgen receptor-expressing tumors had a clinical benefit, including a patient with an estrogen receptor-negative disease. Conversely, none of the 3 patients with androgen receptor-negative tumors had a tumor response. Antiandrogen-based therapy showed efficacy in metastatic male breast cancer patients. Our results encourage considering antiandrogens in the therapeutic continuum, especially if supported by androgen receptor expression.

KW - Androgen receptor

KW - Antiandrogens

KW - Cyproterone acetate

KW - GnRH analogs

KW - Metastatic male breast cancer

UR - http://www.scopus.com/inward/record.url?scp=84922074874&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84922074874&partnerID=8YFLogxK

U2 - 10.1007/s10549-014-3138-9

DO - 10.1007/s10549-014-3138-9

M3 - Article

C2 - 25238881

AN - SCOPUS:84922074874

VL - 148

SP - 73

EP - 80

JO - Breast Cancer Research and Treatment

JF - Breast Cancer Research and Treatment

SN - 0167-6806

IS - 1

ER -